SOLMAZ SUSAM, NECİP İLHAN, Nevin LLHAN, Mehmet AKBULUT

Koroner Arter Hastalarında Plazma Endotelyal Lipaz ve İnflamasyon Belirteçleri Düzeylerinin Değerlendirilmesi

Amaç: Bu çalışmada koroner kalp hastalarının endotelyal lipaz ve seçili diğer inflamatuvar belirteçlerin plazma düzeylerinin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: Çalışma grupları; Fırat Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalına başvuran yaşları 18-80 arasında değişen anjiyografik olarak koroner arter hastalığı tanısı konmuş 88 hasta ile yine anjiyografi sonucu koroner arter hastalığı olmadığı tespit edilmiş 88 sağlıklı bireyden oluşturuldu. Bireylerin plazma örneklerinde, endotelyal lipaz (EL), interlökin 10 (IL-10), IL-6 ve yüksek hassasiyetli C-reaktif protein (hsCRP) düzeyleri enzyme-linked immuno sorbent assay (ELISA) yöntemiyle kit prosedürüne uygun olarak tayin edildi. Bulgular: Plazma EL, IL-10, IL-6 ve hsCRP düzeyleri kontrol ve koroner arter hasta grubunda karşılaştırıldığında; IL-6 ve hsCRP düzeyleri koroner arter hastalarında istatiksel olarak artmış (p

Evaluation of Plasma Le ve ls of Endothe lial Lipase and Inflammatory Marke rs in Patie nts with C oronary Arte ry O bje ctive: It was aimed to evaluate levels of plasma endothelial lipase (EL) and selected inflammatory markers in coronary artery disease (CAD) in this study. Mate rial and Method: T he study groups consisted of 88 patients between the ages of 18 and 80 who referred to the Department of Cardiology, Faculty of Medicine at Fırat University with the diagnosis of coronary artery disease, and 88 healthy individuals reported to have no coronary artery disease after angiography. Plasma endothelial lipase (EL), interleukin 10 (IL-10), interleukin-6 (IL-6) and high sensitivity C-reactive protein (hsCRP) levels were determined by Enzyme-Linked Immuno Sorbent Assay (ELISA) according to the kit procedure. Re sults: When compared to plasma EL, IL-10, IL-6 and hsCRP levels between control and coronary artery disease group; the levels of IL-6 and hsCRP were increased (p<0.01) however, IL-10 levels decreased statistically significant (p<0.05). In terms of EL levels, there was no statist ically significant relationship found between both groups (p>0.05). C onclusion: According to the findings obtained from the study, it was suggested that changes in plasma inflammatory markers levels may play a role in development and progression of CAD.

PDF

___

Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update: a re- port from the American Heart Association. Cir- culation 2014; 129: 28-292.

Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cho- lesterol transport. Circ Res 2005; 96: 1221-32.

Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipop- rotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010; 74: 2263-70.

Ross R. Atherosclerosis -an inflammatory disea- se. N Engl J Med 1999; 340:115-26.

Tedgui A, Mallat Z. Cytokines in atherosclero- sis: pathogenic and regulatory pathways. Phy- siol Rev 2006; 86: 515-81.

Kanda T, Takahashi T. Interleukin-6 and cardi- ovascular diseases. Jpn Heart J 2004; 45: 183

Ji QW, Guo M, Zheng JS, et al. Downregulation of T helper cell type 3 in patients with acute co- ronary syndrome. Arch Med Res 2009; 40: 285-

Kilic T, Ural D, Ural E, et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. He- art 2006; 92: 1041-6.

Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: -2.

Libby P, Ridker PM. Inflammation and athe- rosclerosis: role of C-reactive protein in risk as- sessment. J Med 2004; 116: 9-16.

Okrainec K, Banerjee DK, Eisenberg MJ. Coro- nary artery disease in the developing world. Am Heart J 2004; 148: 7-15.

Yasuda T, Ishida T, Rader DJ. Update on the role of endothelial lipase in high-density lipop- rotein metabolism, reverse cholesterol transport, and atherosclerosis. Circ J 2010; 74: 2263-70.

Ishida T, Choi SY, Kundu RK, et al. Endothelial lipase modulates susceptibility to atherosclero- sis in apolipoprotein-E-deficient mice. J Biol Chem 2004; 279: 45085-92. van der Giet M, Tolle M, Pratico D, et al. Inc- reased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease. J Mol Med 2010; 88: -83.

Zhang J, Yu Y, Nakamura K et al. Endothelial lipase mediates HDL levels in normal and hy- perlipidemic rabbits. J Atheroscleros Thrombos. ; 19: 213-26. Ko KW, Paul A, Ma K, Li L. Chan L. Endothe- lial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice. J Lipid Res 2005; 46: 2586-94.

Sugita T, Watarida S, Katsuyama K, Nakajima Y, Yamamoto Y, Mor A. Interleukin-10 con- centration in children undergoing cardiopulmo- nary bypass. J Thorac Cardiovasc Surg 1996; : 1127-8.

Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in- normal subjects and patients with asthma. J Al- lergy Clin Immunol 1996; 97: 1288-96.

Hansson G, Robertson AL, Soderberg-Naucler C. Inflammation and Atherosclerosis. Annu Rev Pathol Mech Dis 2006; 1: 297-329.

Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: 17-24.

Mallat Z, Heymes C, Ohan J, Faggin E, Lesèche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques. Arte- rioscler Thromb Vasc Biol 1999; 19: 611- 16.

Galkina E, Ley K. Immune and ınflammatory mechanisms of atherosclerosis. Ann Rev Immu- nol 2009; 27: 165-97.

Tedgui A, Mallat Z. Cytokines in atherosclero- sis: Pathogenic and regulatory pathways. Physi- ological Reviews 2006; 86: 515-81.

Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of in- terleukin-6 in human disease. Ann Intern Med ; 128: 127-37. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interluekin-8 protein and gene expression in human arterial atherosclerotic wall. Atheroscle- rosis 1996; 127: 263-71.

Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascu- lar events: results from the Health ABC study. Circulation 2003; 108: 2317-22.

Liu Y, S.Y. Berthier-Schaad MD, Fallin, NE, et al. IL-6 Haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic di- alysis cohort. J Am Soc Nephrol 2006; 17: 863-

Cushman M, Arnold AM, Psaty BM et al. C- reactive protein and the 10-year incidence of co- ronary heart disease in older men and women: the cardiovascular health study. Circulation ; 112: 25-31. Khera A, de Lemos JA, Peshock RM et al. Rela- tionship between C-reactive protein and subcli- nical atherosclerosis: the Dallas Heart Study. Circulation 2006;113: 38-43.

Boekholdt SM, Hack CE, Sandhu MS et al. C- reactive protein levels and coronary artery dis e- ase incidence and mortality in apparently h e- althy men and women: the EPIC-Norfolk pros- pective population study 1993-2003. Atherosc- lerosis 2006; 187; 415-22.

Zebrack JS, Muhlestein JB, Horne BD, Ander- son JL; Intermountain Heart Collaboration Study Group. C reactive protein and angiograp- hic coronary artery disease: independent and additive predictors of risk in subjects with angi- na. J Am Coll Cardiol 2002; 39: 632-7.

Niccoli G, Biasucci LM, Biscione C, et al. In- dependent prognostic value of Creactive protein and coronary artery disease extent in patients af- fected by unstable angina. Atherosclerosis ;196:779-85. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Eng J Med 1997; 336: 973-9.

Memon L, Spasojevic Kalimanovska V, Boga- vac-Stanojevıc N, et al. Assosiciation of C- recative protein with the presence and extent of angiographically verified coronary artery disea- se. Tohoku J Exp Med 2006; 209: 197-206.